Why cholesterol as a central theme in coronary artery disease?

American Journal of Cardiology

Volumn 82, Issue 10 B, 1998, Pages

  Sacks, Frank M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIET; HUMAN; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; NORMAL VALUE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 0032428189     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00717-6     Document Type: Conference Paper

References (41)

1. LaRosa J.C., Hunninghake D., Bush D., Criqui M.H., Getz G.S., Gotto A.M. Jr, Grundy S.M., Rakita L., Robertson R.M., Weisfeldt M.L., Cleeman J.I. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol and coronary artery disease. A joint statement by the American Heart Association and the National Heart, Lung and Blood Institute. Circulation. 81:1990;1721-1733.
2. Carleton R.A., Dwyer J., Finberg L., Flora J., Goodman D.S., Grundy S.M., Havas S., Hunter G.T., Kritchevsky D., Lauer R.M., Leupker R.V., Ramirez A.G., Van Horn L., Stason W.B., Stokes J. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. A statement from the National Cholesterol Education Program. Circulation. 83:1991;2154-2232.
3. Kannel W.B. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 76:(suppl):1995;69C-77C.
4. Rose G., Hamilton P.J., Keen H., Reid D.D., McCartney P., Jarrett R.J. Myocardial ischemia, risk factors and death from coronary heart disease. Lancet. i:1997;105-109.
5. Martin J.M., Hulley S.B., Browner W.S., Kuller L.H., Wentworth D. Serum cholesterol, blood pressure and mortality implications from a cohort of 361,662 men . Lancet. ii:1986;933-936.
6. Pekkanen J., Linn S., Heiss G., Suchindran C.M., Leon A., Rifkind B.M., Tyroler H.A. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre-existing cardiovascular disease. N Engl J Med. 322:1990;1700-1707.
7. Castelli W.P., Abbott R.D., McNamara P.M. Summary estimates of cholesterol used to predict coronary heart diseases. Circulation. 67:1983;730-734.
8. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R. Jr, Bangdiwala S., Tyroler H.A. High-density-lipoprotein cholesterol and cardiovascular disease four prospective American studies . Circulation. 79:1989;8-15.
9. Rifkind B.M. High-density-lipoprotein cholesterol and coronary artery disease survey of the evidence . Am J Cardiol. 66:(suppl):1990;3A-6A.
10. Wilson P.W. High-density lipoprotein, low-density lipoprotein and coronary artery disease. Am J Cardiol. 66:(suppl):1990;7A-10A.
11. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol (Adult Treatment Panel II). Circulation. 89:1994;1329-1445.
12. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H. A prospective study of lipids, apolipoproteins, and risks of myocardial infarction. N Engl J Med. 325:1991;373-381.
13. Kinosian B., Glick H., Garland G. Cholesterol and coronary heart disease predicting risks by levels and ratios . Ann Intern Med. 121:1994;641-647.
14. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density cholesterol level a meta-analysis of population-based prospective studies . J Cardiovasc Risk. 3:1996;213-219.
15. Davignon J., Cohn J.S. Triglycerides a risk factor for coronary heart disease . Atherosclerosis. 124:(suppl):1996;S57-S64.
16. A cooperative trial in the primary prevention of ischemic heart disease using clofibrate Report from the Committee of Principal Investigators . Br Heart J. 40:1978;1069-1118.
17. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 251:1984;351-364.
18. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 251:1984;365-374.
19. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med. 317:1986;1237-1245.
20. Buchwald H., Varco R.I., Matts J.P., Long J.M., Fitch L.L., Campbell G.S. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of Hyperlipidemias (POSCH). N Engl J Med. 323:1990;946-955.
21. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
22. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307.
23. Genest J. Jr, McNamara J.R., Ordovas J.M., Jenner J.L., Silberman S.R., Anderson K.M., Wilson P.W., Salem D.N., Schaefer E.J. Lipoprotein cholesterol, apolipoprotein A-I and B, and lipoprotein (a) abnormalities in men with premature coronary heart disease. J Am Coll Cardiol. 19:1992;792-802.
24. Rubins H.B., Robins S.J., Collins D., Iranmanesh A., Wilt T.J., Mann D., Mayo-Smith M., Faas F.H., Elam M.B., Rutan G.H. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol. 75:1995;1196-1201.
25. Sacks F.M., Pfeffer M.A., Moyé L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events trial investigators. N Engl J Med. 335:1996;1001-1009.
26. Sacks F.M., Moyé L.A., Davis B.R., Cole T.G., Rouleau J.L., Nash D.T., Pfeffer M.A., Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 97:1998;1446-1452.
27. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study. Circulation. 97:1998;1440-1445.
28. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K., Wilhelmsen L., Haghfelt T., Thorgeirsson G., Pyörälä K., Miettinen T., Christophersen B., Tobert J.A., Musliner T.A., Cook T.J. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1998;1453-1460.
29. Grundy S.M. Statin trials and goals of cholesterol-lowering therapy. Circulation. 97:1998;1436-1439.
30. Purnell J.Q., Brunzell J.D. The central role of dietary fat, not carbohydrate, in the insulin resistance syndrome. Curr Opin Lipidol. 8:1997;17-22.
31. Reaven G.M. Do high carbohydrate diets prevent the development or attenuate the manifestations (or both) of syndrome X? A viewpoint strongly against. Curr Opin Lipidol. 8:1997;23-27.
32. Jenkins D.J., Goff D.V., Leeds A.R., Alberti K.G., Wolever T.M., Gassull M.A., Hockaday T.D. Unabsorbable carbohydrate and diabetes decreased postprandial hyperglycemia . Lancet. ii:1976;172-174.
33. Sacks FM. Dietary prevention trials. In: Hennekens CH, Buring J, Furberg C, Manson J, eds. Clinical Trials in Cardiovascular Disease. Philadelphia: WB Saunders, 1998: in press.
34. Low-fat diet in myocardial infarction. Lancet. ii:1965;501-504.
35. Burr M.L., Fehily A.M., Gilbert J.F., Rogers S., Holliday R.M., Sweetnam P.M., Elwood P.C., Deadman N.M. Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction Diet and Reinfarction Trial (DART) . Lancet. ii:1989;757-761.
36. Clofibrate and niacin in coronary heart disease. JAMA. 231:1975;360-381.
37. Dayton S., Pearce M.L., Hashimoto S., Dixon W.J., Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation. 40:(suppl II):1969;II-1-II-63.
38. Controlled trial of soya-bean oil in myocardial infarction. Lancet. ii:1968;693-700.
39. Turpeinen O., Karvonen M.J., Pekkarinen M., Miettinen M., Elosuo R., Paavilainen E. Dietary prevention of coronary heart disease the Finnish Mental Hospital Study . Int J Epidemiol. 8:1979;99-118.
40. Leren P. The Oslo Diet-Heart Study eleven year report . Circulation. 42:1970;935-942.
41. De Lorgeril M., Salen P., Martin J.L., Mamelle N., Monjaud I., Touboul P., Delaye J. Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments. J Am Coll Cardiol. 28:1996;1103-1108.